Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
By A. Stopeck, A. Lipton, J. Body, G. Steger, K. Tonkin, R. De Boer, M. Lichinitser, Y. Fujiwara, D. Yardley, M. Viniegra and 5 more. Journal of Clinical Oncology, 2010
1,514 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology, Surgery
View Paper: https://www.semanticscholar.org/paper/0ffb9ae780ad00092676696d0ddded6b759bd301
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- T. Dodson
- R. Goodday
- T. Aghaloo
- B. Mehrotra
- M. Akram
- M. Daniyal
- Mehwish Iqbal
- A. U. Khan
Citations in the corpus
- Medication-Related Osteonecrosis of the Jaw—2014 Update (2014, background): “doses of BPs and Dmab would be consistent with this contention.((14,62,120)) In Beagle dogs treated with high doses of BPs, areas of necrosis in the mandible sometimes develop, with nonviable osteocytes in the affected bone.”
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus (2015, neutral): “The association of ONJ with potent antiresorptive drugs((62,69)) and the increased risk with higher doses of BPs and Dmab would be consistent with this contention.((14,62,120)) In Beagle dogs treated with high doses of BPs, areas of necrosis in the mandible sometimes develop, with nonviable osteocyt”
- Awareness and current knowledge of breast cancer (2017, background): “It is demonstrated that denosumab is possible therapeutic alternative for individual with bone metastases [257].”